Octapharma Unveils Phase 3 Study Results for Innovative Treatment of Pediatric PANS Octapharma has disclosed promising findings from a Phase 3 study exploring the effectiveness of PANZYGA for Pediatric Acute-onset Neuropsychiatric Syndrome.

Octapharma Unveils Phase 3 Study Results for Innovative Treatment of Pediatric PANS #USA #Paramus #Pans #Octapharma #PANZYGA